Br Med J (Clin Res Ed). 1984 Sep 1;289(6444):525-8. doi: 10.1136/bmj.289.6444.525.
In a preliminary study to compare the effects of different doses of omeprazole 44 patients with endoscopically diagnosed duodenal ulceration randomly received omeprazole 20 mg, 30 mg, 40 mg, or 60 mg daily for four weeks. After four weeks the ulcer had healed in 41 of the 43 patients who completed the course of treatment; the proportions of patients whose ulcer healed were similar between the four dosage groups. Most patients were symptom free after one week of treatment. Seven patients reported a total of eight adverse events. With the exception of one patient who had persistent nausea and was withdrawn from the study, all the adverse events resolved spontaneously during continued treatment with the same dose of omeprazole. Pentagastrin tests were performed before the study and after four weeks' treatment. The mean inhibition of peak acid output measured 24 hours after the last dose was 61%, 94%, 91%, and 81% with omeprazole 20 mg, 30 mg, 40 mg, and 60 mg respectively. During the first six months after the end of treatment 11 out of 36 patients had a symptomatic, endoscopically diagnosed recurrence of ulceration; the median time to relapse was 10 (range 6-23) weeks.
在一项比较不同剂量奥美拉唑效果的初步研究中，44例经内镜诊断为十二指肠溃疡的患者被随机分为四组，分别每日服用20毫克、30毫克、40毫克或60毫克奥美拉唑，疗程为四周。四周后，在完成治疗疗程的43例患者中，有41例溃疡愈合；四个剂量组中溃疡愈合的患者比例相似。大多数患者在治疗一周后症状消失。7例患者共报告了8起不良事件。除1例患者持续恶心并退出研究外，所有不良事件在继续使用相同剂量奥美拉唑治疗期间均自发缓解。在研究前和治疗四周后进行了五肽胃泌素试验。末次给药24小时后测得的最大酸分泌平均抑制率，使用20毫克、30毫克、40毫克和60毫克奥美拉唑时分别为61%、94%、91%和81%。在治疗结束后的前六个月，36例患者中有11例出现有症状的、经内镜诊断的溃疡复发；复发的中位时间为10周（范围6 - 23周）。
